22102From Glycemic Control to Cardiorenal Protection: Improving Outcomes With SGLT2 Inhibitors

Experts Dr. Lawrence Leiter (Chair), Dr. Jennifer Green, Dr. Javed Butler, and Dr. David Cherney from multiple specialties (endocrinology, cardiology, and nephrology) will through lecture, case presentations, and panel discussion, provide perspectives on translating evidence into clinical practice and indicate considerations for using SGLT2 inhibitors safely and effectively in patients with, and at high risk for CV disease, HF, and chronic kidney disease (CKD).

In this program, the following overarching needs of diabetologists/endocrinologists will be addressed: 1) to interpret evidence from cardiovascular (CV), heart failure (HF), and renal outcome trials with SGLT2 inhibitors, 2) to improve awareness of changes in clinical practice guidelines and new scientific statements from diabetes, CV, and renal societies based on this increasing evidence, and 3) to apply patient-centered and interdisciplinary, collaborative care in the treatment of patients with comorbidities with SGLT2 inhibitors. SGLT2 inhibitors not only enable patients with type 2 diabetes (T2D) to achieve glycemic control; they provide cardiorenal protection via mechanisms, still undetermined, independent of glucose-lowering. In this educational initiative, experts Dr. Lawrence Leiter (Chair), Dr. Jennifer Green, Dr. Javed Butler, and Dr. David Cherney from multiple specialties (endocrinology, cardiology, and nephrology) will through lecture, case presentations, and panel discussion, provide perspectives on translating evidence into clinical practice and indicate considerations for using SGLT2 inhibitors safely and effectively in patients with, and at high risk for CV disease, HF, and chronic kidney disease (CKD).

Login to your Account